Compass Therapeutics, Inc.

NasdaqCM:CMPX Stock Report

Market Cap: US$243.4m

Compass Therapeutics Management

Management criteria checks 2/4

Compass Therapeutics' CEO is Tom Schuetz, appointed in May 2024, has a tenure of 10.33 years. total yearly compensation is $3.09M, comprised of 18.6% salary and 81.4% bonuses, including company stock and options. directly owns 4.04% of the company’s shares, worth $9.45M. The average tenure of the management team and the board of directors is 1.8 years and 3.3 years respectively.

Key information

Tom Schuetz

Chief executive officer

US$3.1m

Total compensation

CEO salary percentage18.6%
CEO tenure1yr
CEO ownership4.0%
Management average tenure1.8yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

Sep 28
We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

Jun 05
We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

Feb 13
We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

Sep 20
Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial

Oct 11

CEO Compensation Analysis

How has Tom Schuetz's remuneration changed compared to Compass Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$3mUS$575k

-US$49m

Sep 30 2024n/an/a

-US$48m

Jun 30 2024n/an/a

-US$47m

Mar 31 2024n/an/a

-US$45m

Dec 31 2023US$5mUS$575k

-US$42m

Sep 30 2023n/an/a

-US$41m

Jun 30 2023n/an/a

-US$43m

Mar 31 2023n/an/a

-US$40m

Dec 31 2022US$2mUS$550k

-US$39m

Sep 30 2022n/an/a

-US$41m

Jun 30 2022n/an/a

-US$35m

Mar 31 2022n/an/a

-US$82m

Dec 31 2021US$5mUS$4k

-US$82m

Sep 30 2021n/an/a

-US$78m

Jun 30 2021n/an/a

-US$81m

Mar 31 2021n/an/a

-US$31m

Dec 31 2020US$3mUS$4k

-US$29m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$27m

Mar 31 2020n/an/a

-US$30m

Dec 31 2019US$1mUS$400k

-US$35m

Compensation vs Market: Tom's total compensation ($USD3.09M) is above average for companies of similar size in the US market ($USD1.68M).

Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.

CEO

Tom Schuetz (63 yo)

1yr

Tenure

US$3,093,057

Compensation

Dr. Thomas J. Schuetz, also known as Tom, M.D., Ph.D. was co-founded of Compass Therapeutics, Inc in 2014 and he serves as its CEO since May 28, 2024. He also served as President since May 28, 2024 until 2...

Leadership Team

NamePositionTenureCompensationOwnership
Thomas Schuetz
CEO & Vice Chairman1yrUS$3.09m4.04%
$ 9.8m
Barry Shin
Chief Financial Officerless than a yearUS$1.55m0%
$ 0
Jonathan Anderman
Senior VP3.8yrsUS$893.64k0.015%
$ 37.0k
Vered Bisker-Leib
Advisorno dataUS$7.30m2.5%
$ 6.1m
Neil Lerner
Senior VP & Chief Accounting Officerless than a yearno data0.23%
$ 563.2k
Anna Gifford
Communications Managerno datano datano data
Minori Rosales
Senior VP & Head of Clinical Development2yrsno datano data
Karin Herrera
Senior VP & Head of Clinical Operations2yrsno datano data
James Kranz
VP and Head of Chemistry Manufacturing & Controls1.8yrsno datano data

1.8yrs

Average Tenure

57yo

Average Age

Experienced Management: CMPX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Thomas Schuetz
CEO & Vice Chairman10.3yrsUS$3.09m4.04%
$ 9.8m
Carl Gordon
Independent Chairman10.3yrsUS$110.68k0%
$ 0
Daniel Von Hoff
Member of Clinical Advisory Board3.3yrsno datano data
Ellen Chiniara
Independent Director3.1yrsUS$105.68k0%
$ 0
Philip Ferneau
Independent Director10.3yrsUS$100.68k0%
$ 0
Richard Lindahl
Independent Director2.1yrsUS$100.68k0%
$ 0
Mary Gray
Independent Director3.1yrsUS$91.93k0%
$ 0
James Boylan
Independent Director2.5yrsUS$105.92k0%
$ 0
F. Hodi
Member of Clinical Advisory Board5.6yrsno datano data
Patricia M. LoRusso
Member of Clinical Advisory Board3.3yrsno datano data
Richard Goldberg
Member of Clinical Advisory Board3.3yrsno datano data
Howard Hochster
Member of Clinical Advisory Board3.3yrsno datano data

3.3yrs

Average Tenure

62yo

Average Age

Experienced Board: CMPX's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/08 23:30
End of Day Share Price 2025/05/08 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Compass Therapeutics, Inc. is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aydin HuseynovBenchmark Company
Mayank MamtaniB. Riley Securities, Inc.
Justin WalshB. Riley Securities, Inc.